Synthetic small interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia(+) acute myeloid leukaemia

Clinical and Experimental Medicine

Volumn 6, Issue 1, 2006, Pages 45-47

  Koldehoff, M ^a   Steckel, N K ^a   Beelen, D W ^a   Elmaagacli, A H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

bcr abl; Ph1(+)AML; Small interfering RNAs

Indexed keywords

BCR ABL ANTIBODY; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; IMATINIB; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CASE REPORT; CONTROLLED STUDY; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LETTER; LEUKEMIA CELL; MALE; MYELOABLATIVE CONDITIONING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RNA, SMALL INTERFERING;

EID: 33645120648     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-006-0093-8     Document Type: Letter

References (11)

1. Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375-2384
2. Paietta E, Racevskis J, Bennet JM, Neuberg D, Cassileth PA, Rowe JM, Wiernik PH (1998) Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 12:1881-1885
3. Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T (2004) Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 103:3644-3654
4. Jentsch-Ullrich K, Pelz AF, Braun H, Koenigsmann M, Mohren M, Wieacker P, Franke A (2004) Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica 89:ECR15
5. Ito K, Tominaga K, Suzuki T, Jinnai I, Bessho M (2005) Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. Int J Hematol 81:242-245
6. Viniou N-A, Vassilakopoulos TP, Giakoumi X, Mantzouranis M, Pangalis GA (2004) Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1(+) acute myeloid leukaemia. Eur J Haematol 72:58-60
7. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498
8. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101:1566-1569
9. Wohlbold L, Van Der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (ST571). Blood 102:2236-2239
10. Elmaagacli AH, Freist A, Hahn M, Opalka B, Seeber S, Schaefer UW, Beelen DW (2001) Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of bcr-abl fusion transcripts detected using a new real-time polymerase chain reaction method. Br J Haematol 113:1072-1075
11. Elmaagacli AH, Koldehoff M, Peceny R, Klein-Hitpass L, Ottinger H, Beelen DW, Opalka B (2005) WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90:326-334